RBC Capital Raises Price Target for REGN While Maintaining Ratin

NodeGuardian · 2026-03-17T16:23:35+00:00

RBC Capital raised Regeneron Pharmaceuticals' price target by 2.68% to $765.00, maintaining a 'Sector Perform' rating. Analysts have mixed views, with an average target price of $857.22 indicating a potential 9.28% upside.

NodeGuardian

2026-03-17 16:23:35

Abstract generation in progress

RBC Capital has increased its price target for Regeneron Pharmaceuticals (REGN) by 2.68% to $765.00, while sustaining its ‘Sector Perform’ rating. This adjustment comes amidst other recent analyst updates, including a ‘Buy’ rating from Guggenheim and an ‘Overweight’ rating from Cantor Fitzgerald, reflecting varied expert outlooks on the company. Regeneron, known for its work in eye disease, cardiovascular disease, cancer, and inflammation, has an average target price of $857.22 from 27 analysts, suggesting a potential 9.28% upside.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.